Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2920.625 - 2943.562 Dr. Andrea Apolo

And then there's another trial also for patients that are cisplatinum ineligible, the EV303 study. And that one is EV plus PEMBRO again in the neoadjuvant setting and then in the adjuvant setting. And this is the great thing about EV plus PEMBRO is that it doesn't matter whether you are cisplatinum eligible or not. You can get this treatment. So they're, again, sandwiching it.